Which Alzheimer’s patients are suitable for Donanemab?

Donanemab (Donanemab) is an innovative antibody drug for patients with Alzheimer's disease (AD). It is specifically designed to remove abnormal accumulation of β- amyloid plaques in the brain. β-Amyloid is considered to be one of the key pathological factors in the pathogenesis of Alzheimer's disease, and its accumulation can lead to nerve cell damage and cognitive function decline. By targeting these plaques, donexumab helps slow the progression of the disease and is particularly suitable for use in patients with early- to mid-stage Alzheimer’s disease.

Specifically, donenezumab is mainly suitable for patients with mild cognitive impairment (MCI) or early Alzheimer's disease who have had significant amyloid deposition confirmed by PET scans or cerebrospinal fluid testing. Such patients usually present with mild memory loss or decline in cognitive function, but their ability to perform daily activities is not yet severely impaired. Early use of donenemumab can help delay the progression of the disease and improve the patient's quality of life.

In addition, doneximab is not suitable for patients whose disease has progressed to the mid-to-late stage and whose cognitive impairment is severe, because at this time the neuronal damage is more extensive and the effect of clearing amyloid is limited. In addition, patients with active brain diseases, severe cardiopulmonary insufficiency, or allergies to drug ingredients should not use it. The indications and contraindications need to be evaluated under the guidance of a professional doctor.

In summary, donenezumab is suitable for patients with Alzheimer's disease who have clear amyloid deposition and are in the early stages of cognitive impairment. It provides new hope for such patients through precise targeted therapy, but a comprehensive evaluation should be carried out before use and under the supervision of a doctor to ensure safety and effectiveness.

Reference materials:https://www.drugs.com